Novonesis (Novozymes) A/S risk profile

47 Elevated one input has moved against it

Measured 1 September 2026 from NSIS-B's filed statements. Recomputed nightly.

47 (Elevated), driven by Competitive position at 60, over 3 weighted categories on the MANUFACTURER profile.

What is measured

MechanismReadingBandDirectionDriver
Market expectation20NormalStableOne-year price volatility — 27.5%
Operating pressureReads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company.
Cash conversion16ContainedStableCapital spending against operating cash — 0.34x
Leverage and coverageReads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company.
Competitive position60StretchedStableRevenue-growth gap against peers — -83.8 percentage points
ConcentrationReads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company.

These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.

Basic Materials companies with a risk reading

Financials, valuation and price history for Novonesis (Novozymes) A/S